<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The aim of the present study was to assess the role of the insulin-like growth factor (IGF) system and <z:chebi fb="23" ids="18059">lipids</z:chebi> in predicting the carotid intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 239 type 2 diabetic participants in the <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> Intervention and Event Lowering in <z:mp ids='MP_0002055'>Diabetes</z:mp> (FIELD) Study (76 women) aged 50-75 years were examined before <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> intervention </plain></SENT>
<SENT sid="2" pm="."><plain>Patients underwent carotid ultrasonography for determination of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>IGF-I, IGF binding protein 1 (IGFBP-1), IGFBP-3, cholesterol, <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>, <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (apoB), <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a) (Lp(a)), <z:chebi fb="105" ids="17234">glucose</z:chebi>, HbA(1c), and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> were measured in fasting samples </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were divided in groups without (n = 168) and with (n = 71) clinical <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Partial correlations adjusted for age, sex, BMI, and <z:mp ids='MP_0002055'>diabetes</z:mp> duration showed an inverse association of IGFBP-1 with C-<z:chebi fb="7" ids="16670">peptide</z:chebi> (r = -0 </plain></SENT>
<SENT sid="6" pm="."><plain>24, P = 0.018) and with maximal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> (r = -0.42, P &lt; 0.001), whereas IGF I and IGFBP-3 correlated positively with several risk-promoting <z:chebi fb="23" ids="18059">lipid</z:chebi> parameters </plain></SENT>
<SENT sid="7" pm="."><plain>In linear regression analysis controlling for age, sex, BMI, <z:mp ids='MP_0002055'>diabetes</z:mp> duration, and presence or absence of oral antihyperglycemic or insulin medication, determinants of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> were age, IGFBP-1, pulse pressure, Lp(a), <z:mp ids='MP_0002055'>diabetes</z:mp> duration, and insulin treatment </plain></SENT>
<SENT sid="8" pm="."><plain>IGFBP-1 persisted in the model for subjects with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In summary, a decrease in IGFBP-1 is a marker of carotid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> thickening in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>